Recombinant Human C5 protein, GST-tagged

• Cat.No.: C5-502H
• Product Overview: Recombinant Human C5 protein(NP_001726)(1418-1676 aa), fused to GST tag, was expressed in E. coli.

Specification

• Source: E. coli
• Species: Human
• Tag: GST
• Form: The purified protein was Lyophilized from sterile PBS (58mM Na2HPO4,17mM NaH2PO4, 68mM NaCl, pH7.). 5 % trehalose and 5 % mannitol are added as protectants before lyophilization.
• Protein length: 1418-1676 aa
• AA Sequence: GSSHAVMDISLPTGISANEEDLKAL VEGVDQLFTDYQIKDGHVILQLNSI PSSDFLCVRFRIFELFEVGFLSPAT FTVYEYHRPDKQCTMFYSTSNIKIQ KVCEGAACKCVEADCGQMQEELDLT ISAETRKQTACKPEIAYAYKVSITS ITVENVFVKYKATLLDIYKTGEAVA EKDSEITFIKKVTCTNAELVKGRQY LIMGKEALQIKYNFSFRYIYPLDSL TWIEYWPRDTTCSSCQAFLANLDEF AEDIFLNGC
• Purity: 90%, by SDS-PAGE with Coomassie Brilliant Blue staining.
• Storage: Short-term storage: Store at 2-8°C for (1-2 weeks).
  Long-term storage: Aliquot and store at -20°C to -80°C for up to 3 months, buffer containing 50% glycerol is recommended for reconstitution. Avoid repeat freeze-thaw cycles.
• Reconstitution: Reconstitute at 0.25 µg/μl in 200 μl sterile water for short-term storage.
  Reconstitution with 200 μl 50% glycerol solution is recommended for longer term storage (see Stability and Storage for more details).

Gene Information

• Gene Name: C5 complement component 5 [ Homo sapiens ]
• Official Symbol: C5
• Synonyms: C5; complement component 5; complement C5; CPAMD4; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; FLJ17816; FLJ17822; MGC142298
• Gene ID: 727
• mRNA Refseq: NM_001735
• Protein Refseq: NP_001726
• MIM: 120900
• UniProt ID: P01031

Reviews

09/29/2019

Whether I am studying protein interactions, cellular localization, or signaling pathways, the C5 protein consistently delivers reliable and reproducible data, enabling significant scientific advancements.

10/23/2018

Its superior purity and stability ensure reliable and accurate results, instilling confidence in my research.

11/20/2016

Their assistance has been invaluable in streamlining my experiments and overcoming obstacles effectively.

Q&As

Can C5 inhibition be a potential therapy for neuroinflammatory conditions such as multiple sclerosis?

Yes, C5 inhibition has shown promise in treating multiple sclerosis by modulating the inflammatory response and reducing damage to the central nervous system.

How is the C5 protein targeted in therapeutic interventions, and what are the available modalities?

C5 can be targeted using monoclonal antibodies, such as eculizumab, which inhibits its activity. This approach has been successful in managing various complement-related disorders.

How is the C5 protein involved in the pathogenesis of diseases like PNH?

In PNH, a mutation leads to uncontrolled complement activation, resulting in the destruction of red blood cells. Inhibiting C5 can prevent this process and improve clinical outcomes.

How does C5 inhibition impact the risk of infections in patients undergoing treatment?

C5 inhibition can increase susceptibility to certain infections. Close monitoring and appropriate preventive measures are essential to manage the infection risk in patients receiving C5-targeted therapies.

What role does C5 play in the progression of inflammatory diseases like rheumatoid arthritis?

In rheumatoid arthritis, C5 contributes to inflammation and joint damage. Targeting C5 in treatment may help mitigate the inflammatory response.